Enveda raises $311M Series E

Enveda discovers medicines by studying the chemistry of nature and translating natural compounds into potential therapeutic candidates. The company announced a $311M Series E on September 23, 2026, from its base in Boulder, US. Investors and valuation were not disclosed in Crunchbase's round record; Lounge adds them as they are reported. It has raised more than $100M in total venture funding.